Renata Cifkova

Bio: Renata Cifkova is an academic researcher from First Faculty of Medicine, Charles University in Prague. The author has contributed to research in topics: Population & Blood pressure. The author has an hindex of 68, co-authored 305 publications receiving 80868 citations. Previous affiliations of Renata Cifkova include Masaryk University & Czechoslovak Academy of Sciences.

The risk profile of patients with acute coronary syndrome treated at IKEM between 2006 and 2013

Abstract: Zastoupeni a zřejmě i význam některých kardiovaskularnich rizikových faktorů se na populacni urovni měni. Cilem teto prace proto bylo popsat soucasný rizikový profil pacientů s akutnim koronarnim syndromem (AKS) a srovnat jej s populacnimi daty z identicke populace.Do studie bylo zahrnuto 946 mužů ve věku 28-65 let a 296 žen ve věku 30-70 let, kteři byli přijati na Kliniku kardiologie IKEM s diagnozou akutniho koronarniho syndromu v letech 2006-2013. Výskyt rizikových faktorů u nemocných byl srovnavan s výskytem rizikových faktorů u populacniho vzorku obyvatel odpovidajiciho věku, který byl vysetřen v ramci projektu Czech post-MONICA v letech 2006-2009. Ve srovnani s kontrolni skupinou 1 400 mužů a 1 016 žen měli nemocni castějsi výskyt vsech rizikových faktorů s výjimkou celkoveho cholesterolu. Muži i ženy s AKS měli obdobnou hodnotu celkoveho cholesterolu (muži 5,41 ± 1,16 mmol/l vs. 5,50 ± 1,08 mmol/l, NS, ženy 5,60 ± 1,25 mmol/l vs. 5,71 ± 1,01 mmol/l, NS), ale vyssi hodnotu LDL cholesterolu (muži 3,66 ± 1,05 mmol/l vs. 3,38 ± 0,93 mmol/l, p < 0,001, ženy 3,67 ± 1,17 mmol/l vs. 3,45 ± 0,91 mmol/l, p < 0,001) a nižsi hodnotu HDL cholesterolu (muži 1,14 ± 0,31 mmol/l vs. 1,28 ± 0,34 mmol/l, p < 0,001, ženy 1,32 ± 0,37 mmol/l vs. 1,60 ± 0,38 mmol/l, p < 0,001). Tyto rozdily jsou zachovany i při vylouceni pacientů a kontrolnich osob, ktere byly leceny statiny. Detailnějsi analýza lipidoveho spektra podle věkových skupin ukazala větsi rozdily mezi nemocnými a kontrolni skupinou v hodnotě LDL cholesterolu předevsim u mladsich pacientů, zatimco hodnoty HDL cholesterolu jsou nižsi ve vsech věkových skupinach. Poměr LDL/HDL cholesterolu tak zůstava u nemocných oproti kontrolam vyssi ve vsech věkových skupinach.Pozitivni rodinna anamneza (RA) předcasneho výskytu ischemicke choroby srdecni (ICHS) u rodiců byla u nemocných s AKS rovněž castějsi (muži 19,8 % vs. 13,9 %, p < 0,001, ženy 25,9 % vs. 18,4 %, p < 0,001) a větsi rozdily byly zaznamenany u mladsich pacientů. U pacientů s pozitivni rodinnou anamnezou se AKS manifestoval v casnějsim věku a věkový rozdil se zvýraznil, pokud byla pozitivni RA spojena s kouřenim nebo hypertenzi. Muži s AKS a pozitivni RA se od ostatnich nemocných lisili pouze vyssim podilem nizkých hodnot (< 1,0 mmol/l) HDL cholesterolu (55,5 % vs. 45,0 %, p < 0,05 mmol/l) a vyssim BMI (29,27 ± 4,79 vs. 28,49 ± 4,29 kg/m2, p < 0,05).Hodnota celkoveho cholesterolu se v soucasne populaci nejevi jako rizikový faktor akutniho koronarniho syndromu. Jako největsi riziko se jevi kouřeni a nizka hodnota HDL cholesterolu, resp. vyssi poměr LDL/HDL cholesterolu. U mladsich osob se jako rizikový faktor navic uplatňuji pozitivni rodinna anamneza předcasneho výskytu ICHS a vyssi hodnota LDL cholesterolu.

ESH statement on detection and punishment of abstract fraud and poster plagiarism.

Abstract: The European Meeting on Hypertension was organized for the 15th time in Milan in June 2005. Every second meeting takes place in Milan; after the record turnout of more than 8000 delegates at the 14...

Statins and hypertension

Abstract: Cardiovascular disease (CVD) remains the leading cause of death in developed countries [1]. Hypertension and dyslipidaemia are two major CVD risk factors highly prevalent either alone or in combination [2]. Hypertension often clusters with other CVD risk factors associated with a markedly increased risk of CV events. The interaction among CVD risk factors is such that the probability of a CV event is frequently greater in patients with only moderate BP and cholesterol abnormalities in the presence of additional risk factors than in patients with isolated marked elevation in BP or cholesterol levels alone [3]. In addition, the majority of CV events in the population occur among individuals with modest levels of several risk factors rather than among those rare persons with extreme values of one risk factor. A major aim of treating hypertension is a maximal decrease in long-term total CV risk. This could only be achieved by treatment of all reversible risk factors and associated conditions in addition to treatment of raised BP per se.

Carotid intima-media thickness in young survivors of acute myocardial infarction

Abstract: BACKGROUND: Carotid intima-media thickness (CIMT) is considered to be a useful surrogate marker of coronary atherosclerosis. However, it is unclear whether this applies to young patients with acute myocardial infarction (AMI), in whom most cases are attributable to the destabilization of focal atheroma.

2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

Abstract: ABCD : Appropriate Blood pressure Control in Diabetes ABI : ankle–brachial index ABPM : ambulatory blood pressure monitoring ACCESS : Acute Candesartan Cilexetil Therapy in Stroke Survival ACCOMPLISH : Avoiding Cardiovascular Events in Combination Therapy in Patients Living with Systolic Hypertension ACCORD : Action to Control Cardiovascular Risk in Diabetes ACE : angiotensin-converting enzyme ACTIVE I : Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events ADVANCE : Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation AHEAD : Action for HEAlth in Diabetes ALLHAT : Antihypertensive and Lipid-Lowering Treatment to Prevent Heart ATtack ALTITUDE : ALiskiren Trial In Type 2 Diabetes Using Cardio-renal Endpoints ANTIPAF : ANgioTensin II Antagonist In Paroxysmal Atrial Fibrillation APOLLO : A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People ARB : angiotensin receptor blocker ARIC : Atherosclerosis Risk In Communities ARR : aldosterone renin ratio ASCOT : Anglo-Scandinavian Cardiac Outcomes Trial ASCOT-LLA : Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm ASTRAL : Angioplasty and STenting for Renal Artery Lesions A-V : atrioventricular BB : beta-blocker BMI : body mass index BP : blood pressure BSA : body surface area CA : calcium antagonist CABG : coronary artery bypass graft CAPPP : CAPtopril Prevention Project CAPRAF : CAndesartan in the Prevention of Relapsing Atrial Fibrillation CHD : coronary heart disease CHHIPS : Controlling Hypertension and Hypertension Immediately Post-Stroke CKD : chronic kidney disease CKD-EPI : Chronic Kidney Disease—EPIdemiology collaboration CONVINCE : Controlled ONset Verapamil INvestigation of CV Endpoints CT : computed tomography CV : cardiovascular CVD : cardiovascular disease D : diuretic DASH : Dietary Approaches to Stop Hypertension DBP : diastolic blood pressure DCCT : Diabetes Control and Complications Study DIRECT : DIabetic REtinopathy Candesartan Trials DM : diabetes mellitus DPP-4 : dipeptidyl peptidase 4 EAS : European Atherosclerosis Society EASD : European Association for the Study of Diabetes ECG : electrocardiogram EF : ejection fraction eGFR : estimated glomerular filtration rate ELSA : European Lacidipine Study on Atherosclerosis ESC : European Society of Cardiology ESH : European Society of Hypertension ESRD : end-stage renal disease EXPLOR : Amlodipine–Valsartan Combination Decreases Central Systolic Blood Pressure more Effectively than the Amlodipine–Atenolol Combination FDA : U.S. Food and Drug Administration FEVER : Felodipine EVent Reduction study GISSI-AF : Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation HbA1c : glycated haemoglobin HBPM : home blood pressure monitoring HOPE : Heart Outcomes Prevention Evaluation HOT : Hypertension Optimal Treatment HRT : hormone replacement therapy HT : hypertension HYVET : HYpertension in the Very Elderly Trial IMT : intima-media thickness I-PRESERVE : Irbesartan in Heart Failure with Preserved Systolic Function INTERHEART : Effect of Potentially Modifiable Risk Factors associated with Myocardial Infarction in 52 Countries INVEST : INternational VErapamil SR/T Trandolapril ISH : Isolated systolic hypertension JNC : Joint National Committee JUPITER : Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin LAVi : left atrial volume index LIFE : Losartan Intervention For Endpoint Reduction in Hypertensives LV : left ventricle/left ventricular LVH : left ventricular hypertrophy LVM : left ventricular mass MDRD : Modification of Diet in Renal Disease MRFIT : Multiple Risk Factor Intervention Trial MRI : magnetic resonance imaging NORDIL : The Nordic Diltiazem Intervention study OC : oral contraceptive OD : organ damage ONTARGET : ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial PAD : peripheral artery disease PATHS : Prevention And Treatment of Hypertension Study PCI : percutaneous coronary intervention PPAR : peroxisome proliferator-activated receptor PREVEND : Prevention of REnal and Vascular ENdstage Disease PROFESS : Prevention Regimen for Effectively Avoiding Secondary Strokes PROGRESS : Perindopril Protection Against Recurrent Stroke Study PWV : pulse wave velocity QALY : Quality adjusted life years RAA : renin-angiotensin-aldosterone RAS : renin-angiotensin system RCT : randomized controlled trials RF : risk factor ROADMAP : Randomized Olmesartan And Diabetes MicroAlbuminuria Prevention SBP : systolic blood pressure SCAST : Angiotensin-Receptor Blocker Candesartan for Treatment of Acute STroke SCOPE : Study on COgnition and Prognosis in the Elderly SCORE : Systematic COronary Risk Evaluation SHEP : Systolic Hypertension in the Elderly Program STOP : Swedish Trials in Old Patients with Hypertension STOP-2 : The second Swedish Trial in Old Patients with Hypertension SYSTCHINA : SYSTolic Hypertension in the Elderly: Chinese trial SYSTEUR : SYSTolic Hypertension in Europe TIA : transient ischaemic attack TOHP : Trials Of Hypertension Prevention TRANSCEND : Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease UKPDS : United Kingdom Prospective Diabetes Study VADT : Veterans' Affairs Diabetes Trial VALUE : Valsartan Antihypertensive Long-term Use Evaluation WHO : World Health Organization ### 1.1 Principles The 2013 guidelines on hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology …

Harmonizing the Metabolic Syndrome A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity

Abstract: A cluster of risk factors for cardiovascular disease and type 2 diabetes mellitus, which occur together more often than by chance alone, have become known as the metabolic syndrome. The risk factors include raised blood pressure, dyslipidemia (raised triglycerides and lowered high-density lipoprotein cholesterol), raised fasting glucose, and central obesity. Various diagnostic criteria have been proposed by different organizations over the past decade. Most recently, these have come from the International Diabetes Federation and the American Heart Association/National Heart, Lung, and Blood Institute. The main difference concerns the measure for central obesity, with this being an obligatory component in the International Diabetes Federation definition, lower than in the American Heart Association/National Heart, Lung, and Blood Institute criteria, and ethnic specific. The present article represents the outcome of a meeting between several major organizations in an attempt to unify criteria. It was agreed that there should not be an obligatory component, but that waist measurement would continue to be a useful preliminary screening tool. Three abnormal findings out of 5 would qualify a person for the metabolic syndrome. A single set of cut points would be used for all components except waist circumference, for which further work is required. In the interim, national or regional cut points for waist circumference can be used.